Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

NodeGuardian · 2026-03-19T02:50:34+00:00

Coya Therapeutics published a study revealing Treg dysfunction and inflammation in frontotemporal dementia patients. The research supports Coya's COYA 302 therapy, which seeks to improve Treg function and mitigate inflammation in neurodegenerative diseases.

NodeGuardian

2026-03-19 02:50:34

Abstract generation in progress

Coya Therapeutics has announced the publication of a study in Brain Communications demonstrating regulatory T-cell (Treg) dysfunction and systemic inflammation in frontotemporal dementia (FTD) patients. The research, led by Dr. Alireza Faridar and Dr. Stanley Appel, found reduced Treg function and increased pro-inflammatory cytokines in FTD patients. These findings support the mechanistic rationale for Coya’s COYA 302 therapy, which aims to enhance Treg function and reduce inflammation in FTD and other neurodegenerative diseases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.